Terray Therapeutics utilizes a closed-loop design-make-test-analyze workflow, integrating high-resolution quantitative data from over two billion target-ligand binding measurements to enhance small molecule drug discovery. The platform accelerates the identification of potent small molecules for various therapeutic targets, addressing the inefficiencies and high costs associated with traditional drug development processes.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BR+1Founders
Product
Problem
Small‑molecule drug discovery is hindered by lengthy synthesis cycles, limited experimental data, and reliance on legacy computational models, resulting in high attrition rates and slow time‑to‑clinic.
Solution
Terray Therapeutics addresses these bottlenecks with an end‑to‑end platform that combines purpose‑built hardware, curated high‑quality datasets, and proprietary artificial‑intelligence algorithms. The system automates the design, synthesis, and testing of candidate molecules, generating large, consistent data streams that feed directly into AI models for rapid hypothesis generation and optimization. By tightly integrating experimental feedback with machine‑learning‑driven predictions, the platform accelerates the identification of viable drug candidates and reduces the number of cycles needed to reach preclinical milestones. The approach enables researchers to explore broader chemical space with higher confidence while maintaining control over data provenance and quality.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to accelerate early‑stage small‑molecule discovery and improve hit‑to‑lead efficiency.
Features
- Custom-built automated synthesis hardware that produces diverse small‑molecule libraries at scale
- Unified data infrastructure that captures assay results, physicochemical properties, and synthesis parameters in real time
- Proprietary AI models that predict potency, selectivity, and developability using the internally generated datasets
- Closed‑loop workflow that iteratively refines molecular designs based on experimental outcomes
- Integrated cheminformatics tools for rapid virtual screening and scaffold hopping within the same platform
- Compatibility with existing laboratory information management systems (LIMS) for seamless data exchange